Company Sarepta Therapeutics Inc Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jun. 26 | Monetary policy is getting even more confusing | |
Jun. 26 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 18-05-31 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 12-12-31 |
Diane Berry
PRN | Corporate Officer/Principal | - | 11-11-30 |
Ryan Brown
LAW | General Counsel | 46 | 17-12-31 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 17-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Director/Board Member | 86 | 10-05-31 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 21-11-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 15-06-01 |
Michael Chambers
BRD | Director/Board Member | - | 22-06-01 |
Kathryn Boor
BRD | Director/Board Member | 65 | 22-06-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 94,523,766 | 89,825,408 ( 95.03 %) | 0 | 95.03 % |
Company contact information
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+20.95% | 127B | |
+23.00% | 116B | |
+25.15% | 27.69B | |
-19.75% | 19.62B | |
-16.57% | 16.26B | |
-16.56% | 15.49B | |
+11.19% | 14.81B | |
-46.65% | 14.39B | |
+148.56% | 11.79B |
- Stock Market
- Equities
- SRPT Stock
- Stock
- Company Sarepta Therapeutics Inc